Undisclosed PLK1 PROTAC / Icure Pharm - LARVOL DELTA

Dandicure “Protac New Drug, Positive Results in Animals…“Development in progress” [Google translation] (Hankyung) - “Kids Cure (40,950 + 0.24%) announced 23 days jungyirago cruise target protease (PRO-suspended) drug development subsidiary dandi cure. Dandicure is a Protak-based anticancer drug development company. Using Protac technology, it has a technology to degrade 'polo-like phosphorylated protein' (PLK1), which is attracting attention as a target for leukemia treatment. The company recently confirmed positive results in the first animal test. In a mouse model, mice receiving 4 mg/kg of body weight of a Protak-based drug showed a tendency to decrease the size of cancer cells. In mice that did not receive the drug, cancer cells continued to grow.”

Preclinical • Hematological Malignancies • Leukemia • Oncology